Badalona

• Safety and Impact of Baricitinib on Cell Surivival Pathways, HIV-1 Reservoir and Inflamation in People With HIV-1 Ended recruitment
  2024-520159-26-00 4 2025-09-17 Human immunodeficency virus
• A study to assess the efficacy and safety of Empasiprubart versus IVIg in adults with Multifocal Motor Neuropathy Ended recruitment
  2024-516473-72-00 5 2025-07-31 Multifocal Motor Neuropathy
• A Study of Zolbetuximab Together with Pembrolizumab and Chemotherapy in Adults with Gastric Cancer Ended recruitment
  2024-519773-19-00 5 2025-07-31 Gastroesophageal Junction Adenocarcinoma
• A study to assess the efficacy and safety of ITI-1284 in the treatment of Agitation Associated with Alzheimer's Dementia Ended recruitment
  2024-514680-26-00 4 2025-07-17 Agitation Associated with Alzheimer’s Dementia
• A Study of Two Doses of Ritlecitinib in People 12 Years of Age and Older with Alopecia Areata Ended recruitment
  2024-519370-40-00 5 2025-07-16 Alopecia areata
• A Phase 2b Study to Assess IMVT-1402 in Participants with Cutaneous Lupus Erythematosus Ended recruitment
  2024-516745-39-00 4 2025-07-11 Cutaneous lupus erythematosus
• A Phase 2, open-label study to evaluate the efficacy and safety of anitocabtagene autoleucel in participants with newly diagnosed multiple m … Ended recruitment
  2024-517020-18-00 4 2025-06-30 Newly diagnosed multiple myeloma according to IMWG criteria
• Phase 1b/2 Study of Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Participants With Advanced Gastric Cancer (Substudy GC) Ended recruitment
  2024-517817-34-00 9 2025-06-18 Gastric Cancer
• PLUG-IN. Phase 2 of pembrolizumab combined with enfortumab vedotin for advanced melanoma patients. Ended recruitment
  2024-514163-26-00 4 2025-06-09 Advanced Melanoma
• Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced NSCLC (Substudy NSCLC) Ended recruitment
  2024-517818-15-00 9 2025-06-06 Non-Small Cell Lung Cancer
• A Phase 3 study to assess efficacy, safety and tolerability of remibrutinib in adult and adolescent patients with moderate to severe hidrade … Ended recruitment
  2024-513282-39-00 5 2025-05-28 Hidradenitis Suppurativa (HS)
• First trial in humans testing the safety and efficacy of IMGN151 in women with recurrent gynaecological cancers Ended recruitment
  2023-506842-22-00 7 2025-05-19 Recurrent endometrial cancer, recurrent epithelial ovarian, fallopian
• Study to test new drug eftilagimod alfa (also known as efti) combined with standard marketed treatments (pembrolizumab and chemotherapy) in … Ended recruitment
  2024-513621-23-00 5 2025-04-18 Advanced/metastatic non-small cell lung cancer (NSCLC)
• Study to evaluate the safety and efficacy of a treatment consisting of immunotherapy by subcutaneous injection of a combination of Der p 1/D … Ended recruitment
  2024-518519-20-01 4 2025-04-10 moderate/severe allergic rhinitis/rhinoconjunctivitis with/without con
• Clinical trial with ivermectin to treat strongyloidiasis with the aim of demonstrating that both the independent and weight-dependent dose o … Ended recruitment
  2024-515968-32-00 4 2025-04-08 Strongyloidiasis is caused by a parasite that is globally distributed
• Clinical trial to evaluate effectiveness and cost-effectiveness of pre-emptive genotyping strategy to optimise tacrolimus dosage in a pretra … Ended recruitment
  2024-516596-32-00 6 2025-03-31 Kidney transplant
• A clinical study of raludotatug deruxtecan in people with gastrointestinal cancers (MK-5909-005) Ended recruitment
  2024-517416-30-00 10 2025-03-31 Gastrointestinal Cancers
• A trial to find the effect of Ginkgo biloba extract EGb 761® and how safe it is in participants with cognitive impairment associated with po … Ended recruitment
  2024-517199-39-00 4 2025-03-19 COGNITIVE IMPAIRMENT ASSOCIATED WITH POST-COVID-19 SYNDROME
• A Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Preventive Treatment of Menstrual Migraine Ended recruitment
  2024-512946-41-00 5 2025-03-05 Menstrual Migraine
• BESTOW-EXTENSION: A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long- Term Safety and Efficacy of Tegoprubart in Kidney … Ended recruitment
  2023-503337-21-00 4 2025-02-28 Prophylaxis of Renal Allograft Rejection
• Phase II proof-of-concept, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of plitidepsin in adults w … Ended recruitment
  2024-516378-31-00 4 2025-02-07 post-COVID-19 Condition (PCC)
• Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 ( ISLEND- … Ended recruitment
  2024-514047-28-00 5 2025-01-27 HIV-1 Infection
• A research study to investigate the effects of CagriSema compared to placebo in people with type 2 diabetes and painful diabetic peripheral … Ended recruitment
  2023-509662-38-00 4 2025-01-22 Type 2 diabetes and painful diabetic peripheral neuropathy
• An open label, single-arm, phase 2 study of perioperative sacituzumab govitecan in combination with zimberelimab and domvanalimab for patien … Ended recruitment
  2023-504420-26-00 4 2025-01-13 Bladder Cancer

Showing 361–384 of 775 trials